Evidence map›Paper›PMID 36768362›Full record

ReviewInternational journal of molecular sciences2023

Spotlight on CYP4B1.

Annika Röder, Saskia Hüsken, Michael C Hutter, Allan E Rettie, Helmut Hanenberg, Constanze Wiek, Marco Girhard

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Annika RöderInstitute of Biochemistry, Heinrich Heine University, 40225 Düsseldorf, Germany.
Saskia HüskenDepartment of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany.
Michael C HutterCenter for Bioinformatics, Saarland University, 66123 Saarbrücken, Germany.ORCID 0000-0003-3168-6554
Allan E RettieDepartment of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, DC 98105, USA.
Helmut HanenbergDepartment of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany.
Constanze WiekDepartment of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany.
Marco GirhardInstitute of Biochemistry, Heinrich Heine University, 40225 Düsseldorf, Germany.ORCID 0000-0002-9054-3628
Heinrich Heine University Düsseldorf · DESaarland University · DEUniversity of Washington · US

Funding

Deutsche Forschungsgemeinschaft GI 1423/2-1Deutsche Forschungsgemeinschaft WI 5377/2-1
6 · The paper itself

Abstract

The mammalian cytochrome P450 monooxygenase CYP4B1 can bioactivate a wide range of xenobiotics, such as its defining/hallmark substrate 4-ipomeanol leading to tissue-specific toxicities. Similar to other members of the CYP4 family, CYP4B1 has the ability to hydroxylate fatty acids and fatty alcohols. Structural insights into the enigmatic role of CYP4B1 with functions in both, xenobiotic and endobiotic metabolism, as well as its unusual heme-binding characteristics are now possible by the recently solved crystal structures of native rabbit CYP4B1 and the p.E310A variant. Importantly, CYP4B1 does not play a major role in hepatic P450-catalyzed phase I drug metabolism due to its predominant extra-hepatic expression, mainly in the lung. In addition, no catalytic activity of human CYP4B1 has been observed owing to a unique substitution of an evolutionary strongly conserved proline 427 to serine. Nevertheless, association of CYP4B1 expression patterns with various cancers and potential roles in cancer development have been reported for the human enzyme. This review will summarize the current status of CYP4B1 research with a spotlight on its roles in the metabolism of endogenous and exogenous compounds, structural properties, and cancer association, as well as its potential application in suicide gene approaches for targeted cancer therapy.

Indexed as

Aryl Hydrocarbon HydroxylasesCytochrome P-450 Enzyme SystemFatty AcidsAnimalsHumansMammalsRabbitsXenobioticsAryl Hydrocarbon Hydroxylasescytochrome P-450 CYP4B1Cytochrome P-450 Enzyme SystemFatty AcidsXenobioticsbioactivationcancerCYP4B1cytochrome P450drug metabolismendobiotic metabolismstructuresuicide genexenobiotics

Identifiers

PMID36768362
PMCPMC9916508
OpenAlexW4317625898

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.